被诅咒的功能性消化不良:定义、发病机制与管理
本文综述功能性消化不良(FD)的定义演变、发病机制假说及治疗策略。罗马进程定义了FD,其发病机制假说从胃感觉运动功能障碍扩展至十二指肠免疫反应与微生物组;抑酸和根除幽门螺杆菌在特定人群有限有效,但基于推测病理生理的大多数对症策略大多失败,缺乏经验证的生物标志物使FD仍是难以捉摸的目标。
要点
- FD定义由罗马进程界定,其标准演变反映诊断复杂性。
- FD发病机制假说从胃感觉运动功能障碍扩展至十二指肠免疫与微生物组。
- 抑酸和根除幽门螺杆菌在特定人群有限有效,基于推测病理生理的策略大多失败。
核心结论
- FD缺乏经验证的生物标志物,仍是难以捉摸的目标,在更好定义其必然包含的各种表型之前很可能持续如此。
研究设计与样本
- 本文为综述,聚焦功能性消化不良(FD)的定义与管理,并回顾罗马标准演变及发病机制假说。
主要发现
- 消化不良症状相对非特异,多种疾病可表现为任一或组合症状,临床医生首要挑战是从症状多属功能性的群体中检出可能患胃癌等潜在危及生命疾病的少数人。
- FD发病机制假说最初聚焦胃感觉运动功能障碍,现已深入十二指肠并考虑免疫反应和微生物组等因素。
- 抑酸和根除幽门螺杆菌在特定人群有有限疗效,但基于推测病理生理改善多数患者症状的策略大多失败。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dyspepsia is an umbrella term used to encompass a number of symptoms thought to originate from the upper gastrointestinal tract. These symptoms are relatively nonspecific; not surprisingly, therefore, a myriad of conditions may present with any one or a combination of these symptoms. Therein lays the clinician's first challenge: detecting the minority who may have a potentially life-threatening disorder, such as gastric cancer, from a population whose symptoms are, for the most part, considered functional in origin. The second challenge lies in the definition and management of those individuals with functional dyspepsia (FD); the major focus of this review. The Rome process has addressed the issue of FD definition and a look back at the evolution of Rome criteria for this disorder illustrates the complexities that have so frustrated us. There has been no shortage of hypotheses to explain symptom pathogenesis in FD; initially focused on gastric sensorimotor dysfunction, these have now strayed well into the duodenum and have come to entertain such factors as immune responses and the microbiome. FD has proven to be an equally challenging area for therapeutics; while the staple approaches of acid suppression and eradication of Helicobacter pylori have some limited efficacy in select populations, strategies to ameliorate symptoms in the majority of sufferers based on presumed pathophysiology have largely foundered. Lacking a validated biomarker(s) FD continues to be an elusive target and is likely to remain so until we can better define the various phenotypes that it must surely contain.
引用
- Koduru P, Irani M, Quigley EMM, et al. Definition, Pathogenesis, and Management of That Cursed Dyspepsia. Clin Gastroenterol Hepatol. 2017. PMID: 28899670. doi:10.1016/j.cgh.2017.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。